BRPI0414506A - combinação de um inibidor de histona desacetilase com um ligante de receptor de morte - Google Patents

combinação de um inibidor de histona desacetilase com um ligante de receptor de morte

Info

Publication number
BRPI0414506A
BRPI0414506A BRPI0414506-2A BRPI0414506A BRPI0414506A BR PI0414506 A BRPI0414506 A BR PI0414506A BR PI0414506 A BRPI0414506 A BR PI0414506A BR PI0414506 A BRPI0414506 A BR PI0414506A
Authority
BR
Brazil
Prior art keywords
death receptor
combination
hdai
pharmaceutical
histone deacetylase
Prior art date
Application number
BRPI0414506-2A
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Kapil N Bhalla
Original Assignee
Novartis Ag
Univ South Florida Board Of Tr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ South Florida Board Of Tr filed Critical Novartis Ag
Publication of BRPI0414506A publication Critical patent/BRPI0414506A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms

Abstract

"COMBINAçãO DE UM INIBIDOR DE HISTONA DESACETILASE COM UM LIGANTE DE RECEPTOR DE MORTE". A invenção refere-se a um método de prevenir ou tratar doenças proliferativas, tais como o câncer, em um mamífero, particularmente um ser humano, com uma combinação de agentes farmacêuticos, a qual compreende: (a) um HDAI; e (b) um ligante de receptor de morte. A invenção adicionalmente refere-se às composições farmacêuticas compreendendo: (a) um HDAI; (b) ligante de receptor de morte; e (c) um veículo farmaceuticamente aceitável. A presente invenção adicionalmente refere-se a um acondicionamento ou produto comercial compreendendo: (a) uma formulação farmacêutica de um HDAI; e (b) uma formulação farmacêutica de ligante de receptor de morte para uso simultâneo, coincidente, separado ou seqüencial.
BRPI0414506-2A 2003-09-18 2004-09-17 combinação de um inibidor de histona desacetilase com um ligante de receptor de morte BRPI0414506A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50465503P 2003-09-18 2003-09-18
PCT/EP2004/010468 WO2005025619A1 (en) 2003-09-18 2004-09-17 Combination of a histone deacetylase inhibitor with a death receptor ligand

Publications (1)

Publication Number Publication Date
BRPI0414506A true BRPI0414506A (pt) 2006-11-07

Family

ID=34312466

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414506-2A BRPI0414506A (pt) 2003-09-18 2004-09-17 combinação de um inibidor de histona desacetilase com um ligante de receptor de morte

Country Status (8)

Country Link
US (1) US20070258972A1 (pt)
EP (1) EP1667720A1 (pt)
JP (1) JP2007505860A (pt)
CN (1) CN1852737A (pt)
AU (1) AU2004271730A1 (pt)
BR (1) BRPI0414506A (pt)
CA (1) CA2539000A1 (pt)
WO (1) WO2005025619A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
JP2009537532A (ja) * 2006-05-15 2009-10-29 セネックス バイオテクノロジー，インク． 腫瘍細胞増殖の選択的阻害剤としてのｃｄｋｉ経路阻害剤
AU2008216327A1 (en) * 2007-02-15 2008-08-21 Novartis Ag Combination of LBH589 with other therapeutic agents for treating cancer
US9238069B2 (en) 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
CN109705057B (zh) * 2017-10-25 2023-05-30 成都先导药物开发股份有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253753T3 (es) * 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2003296310A1 (en) * 2002-12-06 2004-06-30 University Of South Florida Histone deacetylase inhibitor enhancement of trail-induced apoptosis

Also Published As

Publication number Publication date
AU2004271730A1 (en) 2005-03-24
WO2005025619A1 (en) 2005-03-24
EP1667720A1 (en) 2006-06-14
US20070258972A1 (en) 2007-11-08
JP2007505860A (ja) 2007-03-15
CN1852737A (zh) 2006-10-25
CA2539000A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
BRPI0515446A (pt) amidas bicìclicas como inibidores de cinases
BR112014018910A8 (pt) Produto farmacêutico , kit, uso de vemurafenibe, produtos, métodos, composições e usos inovadores
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
CO5271710A1 (es) Combinanciones de un inhibidor de cinasa de tirosina receptora con un compuesto organico capaz de enlazarse con glicorpoteina acido-a
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BRPI0411165A (pt) composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
CR20120009A (es) 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
PT101289A (pt) Utilizacao de taxol para a preparacao de composicoes farmaceuticas de eficacia melhorada
DOP2004000949A (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos
MXPA05004919A (es) Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
BRPI0516883A (pt) compostos e métodos para modulação da atividade de trombopoietina
GT200500020A (es) Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa.
ECSP099483A (es) Combinación de un inhibidor de desacetilasa de histona y un antimetabolito
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
CO5640094A2 (es) Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis de tumor
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
EA200700403A1 (ru) ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
EP3915991A4 (en) PYRROLOPYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF A PROTEIN KINASE RELATED DISEASE COMPRISING IT AS ACTIVE INGREDIENT
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
WO2021074695A8 (en) PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
BRPI0414506A (pt) combinação de um inibidor de histona desacetilase com um ligante de receptor de morte
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.